Richat Abbas
WinnMed(US)Mayo Clinic in Arizona(US)
Publications by Year
Research Areas
Chronic Lymphocytic Leukemia Research, Chronic Myeloid Leukemia Treatments, HER2/EGFR in Cancer Research, PI3K/AKT/mTOR signaling in cancer, Attention Deficit Hyperactivity Disorder
Most-Cited Works
- → Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer(2010)524 cited
- → Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome–positive chronic myeloid leukemia patients with resistance or intolerance to imatinib(2011)458 cited
- → A Phase I Study with Neratinib (HKI-272), an Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor, in Patients with Solid Tumors(2009)302 cited
- → Phase I Study of Neratinib in Combination With Temsirolimus in Patients With Human Epidermal Growth Factor Receptor 2–Dependent and Other Solid Tumors(2013)198 cited
- → A Human Physiologically Based Pharmacokinetic Model for Trichloroethylene and Its Metabolites, Trichloroacetic Acid and Free Trichloroethanol(1998)118 cited
- → Phase I Study of Bosutinib, a Src/Abl Tyrosine Kinase Inhibitor, Administered to Patients with Advanced Solid Tumors(2011)88 cited
- → A Physiologically Based Pharmacokinetic Model for Trichloroethylene and Its Metabolites, Chloral Hydrate, Trichloroacetate, Dichloroacetate, Trichloroethanol, and Trichloroethanol Glucuronide in B6C3F1 Mice(1997)86 cited
- → A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects(2011)83 cited
- → Clinical Pharmacokinetics and Pharmacodynamics of Bosutinib(2016)68 cited
- → Neoadjuvant PF-05280014 (a potential trastuzumab biosimilar) versus trastuzumab for operable HER2+ breast cancer(2018)58 cited